Literature DB >> 16269276

Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS.

Tom Delahunty1, Lane Bushman, Courtney V Fletcher.   

Abstract

An LC/MS/MS assay for the determination of tenofovir (TNF) was developed and validated for use with the EDTA anticoagulated human plasma matrix. Heparin-treated plasma and serum matrices were also validated. After addition of adefovir as an internal standard, trifluoroacetic acid was used to produce a protein-free extract. Chromatographic separation was achieved with a Polar-RP Synergi, 2.0 mm x 150 mm, reversed-phase analytical column. The mobile phase was 3% acetonitrile/1% acetic acid, aq. Detection of TNF and the internal standard was achieved by ESI MS/MS in the positive ion mode using 288/176 and 274/162 transitions, respectively. The method was linear from 10 to 750 ng/ml with a minimum quantifiable limit of 10 ng/ml when 250 microl aliquots were analyzed. The usefulness of this LC/MS/MS method to routinely monitor plasma concentrations of TNF was demonstrated along with its ability to assist in the performance of pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16269276     DOI: 10.1016/j.jchromb.2005.10.015

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  27 in total

1.  Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid.

Authors:  Andrew J Ocque; Colleen E Hagler; Gene D Morse; Scott L Letendre; Qing Ma
Journal:  J Pharm Biomed Anal       Date:  2018-04-23       Impact factor: 3.935

2.  Renal handling of amphotericin B and amphotericin B-deoxycholate and potential renal drug-drug interactions with selected antivirals.

Authors:  František Trejtnar; Jana Mandíková; Jana Kočíncová; Marie Volková
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  Direct and real-time quantification of tenofovir release from ph-sensitive microparticles into simulated biological fluids using (1)h nuclear magnetic resonance.

Authors:  Chi Zhang; Tao Zhang; Nathan A Oyler; Bi-Botti C Youan
Journal:  J Pharm Sci       Date:  2014-04       Impact factor: 3.534

4.  Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs Lopinavir, Ritonavir, and Tenofovir in plasma.

Authors:  Josefin Koehn; Rodney J Y Ho
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

5.  Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.

Authors:  H C Koenig; K Mounzer; G W Daughtridge; C E Sloan; L Lalley-Chareczko; G S Moorthy; S C Conyngham; A F Zuppa; L J Montaner; P Tebas
Journal:  HIV Med       Date:  2017-04-26       Impact factor: 3.180

6.  Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?

Authors:  Peter L Havens; Jennifer J Kiser; Charles B Stephensen; Rohan Hazra; Patricia M Flynn; Craig M Wilson; Brandy Rutledge; James Bethel; Cynthia G Pan; Leslie R Woodhouse; Marta D Van Loan; Nancy Liu; Jorge Lujan-Zilbermann; Alyne Baker; Bill G Kapogiannis; Catherine M Gordon; Kathleen Mulligan
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

7.  Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.

Authors:  Gautam Baheti; Jennifer R King; Edward P Acosta; Courtney V Fletcher
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

8.  Evaluation of degradation kinetics and physicochemical stability of tenofovir.

Authors:  Vivek Agrahari; Sandeep Putty; Christiane Mathes; James B Murowchick; Bi-Botti C Youan
Journal:  Drug Test Anal       Date:  2014-05-12       Impact factor: 3.345

9.  The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards.

Authors:  Tom Delahunty; Lane Bushman; Brian Robbins; Courtney V Fletcher
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-05-21       Impact factor: 3.205

10.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

Authors:  Jennifer J Kiser; Courtney V Fletcher; Patricia M Flynn; Coleen K Cunningham; Craig M Wilson; Bill G Kapogiannis; Hanna Major-Wilson; Rolando M Viani; Nancy X Liu; Larry R Muenz; D Robert Harris; Peter L Havens
Journal:  Antimicrob Agents Chemother       Date:  2007-11-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.